Yeah- I have heard this from a couple different people- I do have my reasons for having it in there- L-Norvaline inhibits arginase, so very little arginine is going to be metabolized by the enzyme. Plus, arginine has the ability to act as a glucose metabolizing agent in skeletal muscle:
Eur Rev Med Pharmacol Sci. 2012 Jun;16(6):816-23.
Effect of 3-month L-arginine supplementation on insulin resistance and tumor necrosis factor activity in patients with visceral obesity.
Invalid Link Removed,
Invalid Link Removed,
Invalid Link Removed,
Invalid Link Removed,
Invalid Link Removed,
Invalid Link Removed,
Invalid Link Removed.
Source
Department of Internal Medicine, Metabolic Disorders and Hypertension, Poznan University of Medical Sciences, Poznan, Poland.
[email protected]
Abstract
BACKGROUND:
The role of tumor necrosis factor alpha (TNF-alpha), one of the adipose tissue products, in the pathogenesis of insulin resistance is well-documented. Many recent studies have shown beneficial influence of L-arginine supplementation on cardiovascular system. However, molecular mechanisms of its positive actions are not fully elucidated.
AIM:
The aim of the study was to evaluate the influence of L-arginine supplementation on tumor necrosis factor alpha, insulin resistance and selected anthropometric and biochemical parameters in patients with visceral obesity.
PATIENTS AND METHODS:
60 patients with visceral obesity were randomly assigned to either receive 9 g of L-arginine or placebo for 3 months. 20 healthy lean subjects were used as control. Selected anthropometrical measurements and blood biochemical analyses were performed at baseline and after 3-months. TNF-alpha and its soluble receptor 2 (sTNFR2) were assessed in both treated groups. Insulin resistance in the participants was evaluated according to the homeostasis model assessment-insulin resistance (HOMA-IR) protocol.
RESULTS:
The concentration of insulin, TNF-a and sTNFR2 and HOMA-IR level in both obese groups significantly exceeded these observed in the control. Basal TNF-alpha and sTNFR2 concentrations were positively correlated with basal body mass index (BMI), waist circumference, percent of body fat and HOMA-IR. We found that 3-month L-arginine supplementation resulted in significant decrease of HOMA-IR and insulin concentration. Only insignificant tendency to decrease of TNF-alpha and sTNFR2 was observed.
CONCLUSIONS:
Our results confirm TNF-alpha role in the complex pathogenesis of insulin resistance in patients with visceral obesity. 3-months L-arginine supplementation in a dose of 9 g improves insulin sensitivity in patients with visceral obesity with no impact on tumor necrosis factor alpha concentration.
J Endocrinol Invest. 2012 Jun 25. [Epub ahead of print]
Supplementation with L-arginine favourably influences plasminogen activator inhibitor type 1 concentration in obese patients - a randomized, double blind trial.
Invalid Link Removed,
Invalid Link Removed,
Invalid Link Removed,
Invalid Link Removed,
Invalid Link Removed,
Invalid Link Removed.
Source
Department of Internal Medicine, Metabolic Disorders and Hypertension, Poznan University of Medical Sciences, Poznan, Poland.
Abstract
Background. Elevated plasminogen activator inhibitor type 1 (PAI 1) plays an important role in the pathogenesis of excess blood coagulability in obese patients. L-arginine supplementation has shown to be associated with enhanced cardiovascular and metabolic health. The aim of the study was to assess the effect of L-arginine supplementation on PAI 1 concentration and to evaluate the relation to changes in nitric oxide (NO) plasma level, insulin sensitivity (M value) and total antioxidant status (TAS) in obese patients. Material/subjects and methods. A randomized, double-blind, placebo-controlled study was conducted from March 2010 to June 2011. 88 obese patients were randomly assigned to receive either 9 g of L-arginine or placebo daily for 6 months. At baseline and after 6 months selected anthropometrical measurements and blood biochemical analyses were performed, and PAI 1, NO, TAS levels were assessed. Insulin sensitivity was evaluated using the hyperinsulinemic euglycemic clamp technique. Results. We found that 6-month L-arginine supplementation resulted in significant decrease of PAI 1. Significant increase of NO, TAS and insulin sensitivity level were noticed. In a group of patients treated with L-arginine negative correlation between a change of insulin sensitivity value and a change of PAI 1 concentration was found. Conclusions. The present findings demonstrate favourable influence of L-arginine supplementation on PAI 1 concentartion in obese patients. Beneficial influence is related to insulin sensitivity improvement. The potential therapeutic role of L-arginine administration in patients with obesity needs further investigation.
Diabetes Obes Metab. 2012 Oct;14(10):893-900. doi: 10.1111/j.1463-1326.2012.01615.x. Epub 2012 May 21.
Effect of a long-term oral l-arginine supplementation on glucose metabolism: a randomized, double-blind, placebo-controlled trial.
Invalid Link Removed,
Invalid Link Removed,
Invalid Link Removed,
Invalid Link Removed,
Invalid Link Removed,
Invalid Link Removed,
Invalid Link Removed,
Invalid Link Removed,
Invalid Link Removed,
Invalid Link Removed,
Invalid Link Removed,
Invalid Link Removed,
Invalid Link Removed.
Source
Cardio-Diabetes and Core Lab Unit, Metabolic and Cardiovascular Science Division, Department of Internal Medicine, San Raffaele Scientific Institute, Milan, ItalyCardio-Metabolism and Clinical Trials Unit, Metabolic and Cardiovascular Science Division, Department of Internal Medicine, San Raffaele Scientific Institute, Milan, ItalyVascular Surgery, Metabolic and Cardiovascular Science Division, Cardio-Thoraco-Vascular Department,San Raffaele Scientific Institute, Milan, ItalyNeurology Department, San Raffaele Scientific Institute, Milan, ItalyCentre for the Study of Atherosclerosis, Department of Pharmacological Sciences, University of Milan, Milan, Italy.
Abstract
Aim: This study assessed the efficacy of long-term l-arginine (l-arg) therapy in preventing or delaying type 2 diabetes mellitus. Methods: A mono-centre, randomized, double-blind, parallel-group, placebo-controlled, phase III trial (l-arg trial) was conducted on 144 individuals affected by impaired glucose tolerance (IGT) and metabolic syndrome (MS). l-Arg/placebo was administered (6.4 g/day) on a background structured lifestyle intervention for 18 months plus a 12-month extended follow-up period after study drug termination. Fasting glucose levels and glucose tolerance after oral glucose tolerance test were evaluated throughout the study. Results: After 18 months, l-arg as compared with placebo did not reduce the cumulative incidence of diabetes [21.4 and 20.8%, respectively, hazard ratio (HR), 1.04; 95% confidence interval (CI), 0.58-1.86] while the cumulative probability to become normal glucose tolerant (NGT) increased (42.4 and 22.1%, respectively, HR, 2.60; 95% CI, 1.51-4.46, p < 0.001). The higher cumulative probability to become of NGT was maintained during the extended period in subjects previously treated with l-arg (HR, 3.21; 95% CI, 1.87-5.51; p < 0.001). At the end of the extended period, the cumulative incidence of diabetes in subjects previously treated with l-arg was reduced as compared with placebo (27.2 and 47.1%, respectively, HR, 0.42; 95% CI, 0.24-0.75, p < 0.05). During both periods, l-arg significantly improved insulin sensitivity and β-cell function. Conclusion: Among persons with IGT and MS, the supplementation of l-arg for 18 months does not significantly reduce the incidence of diabetes but does significantly increase regression to NGT.
Metabolism. 2012 Aug 10. [Epub ahead of print]
L-Arginine enhances glucose and lipid metabolism in rat L6 myotubes via the NO/ c-GMP pathway.
Invalid Link Removed,
Invalid Link Removed,
Invalid Link Removed,
Invalid Link Removed.
Source
Department of Physiology and Biophysics, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil; Section of Integrative Physiology, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Abstract
OBJECTIVE:
The amino acid Arginine (Arg) is the main biological precursor of nitric oxide (NO) and has been described to improve insulin sensitivity in diabetes and obesity. We investigated the molecular mechanisms involved in the long-term effects of Arg on glucose and lipid metabolism.
MATERIALS AND METHODS:
L6 myotubes were treated with Arg (7mmol/L) for 6days. D-Mannitol (7mmol/L) was used as control; spermine NONOate (10μmol/L) and L-NAME (100μmol/L) were used to evaluate the NO/c-GMP pathway role. Basal and insulin-induced (120 nmol/L) glycogen synthesis, glucose uptake and lipid oxidation, c-GMP and nitrite levels, and the intracellular signaling pathways were evaluated.
RESULTS:
Arg-treatment increased: 1) basal and insulin-stimulated glycogen synthesis; 2) glucose uptake; 3) palmitate oxidation; 4) p-Akt (Ser(473)), total and plasma membrane GLUT4 content, total and p-AMPK-α and p-ACC (Ser(79)), p-GSK-3α/β (Ser(21/9)) and 5) nitrite and c-GMP levels. L-NAME treatment suppressed Arg effects on: 1) nitrite and c-GMP content; 2) glycogen synthesis and glucose uptake; 3) basal and insulin-stimulated p-Akt (Ser(473)), total and p-AMPK-α and ACC, and nNOS expression.
CONCLUSION:
We provide evidence that Arg improves glucose and lipid metabolism in skeletal muscle, in parallel with increased phosphorylation of Akt and AMPK-α. These effects were mediated by the NO/c-GMP pathway. Thus, arginine treatment enhances signal transduction and has a beneficial effect of metabolism in skeletal muscle through direct activation of Akt and AMPK pathways.
AKG is in the product for another reason entirely- read the tech write-up and focus on the section regarding mTOR- it will make more sense